Dr. Brian Druker is an Investigator of the Howard Hughes Medical Institute, Director of the Oregon Health & Science University (OHSU) Cancer Institute, and JELD-WEN Chair of Leukemia Research at OHSU. His role in the development of Gleevec® (imatinib) and Gleevec’s application in the clinic have resulted in numerous awards for Dr. Druker including the Warren Alpert Prize from Harvard Medical School, the American Society of Hematology’s Dameshek Prize, the American Cancer Society’s Medal of Honor, the Kettering Prize from General Motors Cancer Research Foundation, and the David A. Karnofsky Award from the American Society of Clinical Oncology. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, and the National Academy of Sciences in 2007. Dr. Druker received his BS degree in chemistry and his M.D. from the University of California, San Diego; he completed his internship and residency in internal medicine at Barnes-Jewish Hospital associated with the Washington University School of Medicine in St. Louis and completed a fellowship in medical oncology at Harvard’s Dana-Farber Cancer Institute. In September 2009, Dr. Druker received the prestigious Lasker Award.